Core Viewpoint - The company achieved significant growth in both revenue and profit in 2025, indicating a strong operational performance and improved profitability metrics [4][5]. Group 1: Financial Performance - In 2025, the company reported a revenue of 1.595 billion, representing an 18.26% year-on-year increase; net profit attributable to shareholders was 154 million, up 36.02%; and net profit excluding non-recurring items was 135 million, reflecting a 14.34% growth [4]. - In Q4 2025, the company achieved a revenue of 494 million, a 33.91% increase year-on-year; net profit attributable to shareholders surged by 274.03% to 42 million; and net profit excluding non-recurring items grew by 11.17% to 23 million [4]. Group 2: Cost Structure and Cash Flow - The company’s sales expense ratio was 24.46%, down by 1.01 percentage points; management expense ratio was 17.86%, up by 0.02 percentage points; financial expense ratio was 1.04%, up by 2.78 percentage points; and R&D expense ratio was 6.97%, down by 0.40 percentage points [5]. - The net cash flow from operating activities increased by 58.77%, driven by growth in Echosens and domestic pharmaceutical segments, as well as increased cash inflows from external units [5]. Group 3: R&D Investment and Innovation - In 2025, the company invested 111 million in R&D, an increase of 11.78% year-on-year [6]. - The company made significant innovations, including the continuous optimization of the liver disease management platform LHM and the advancement of the fourth-generation FibroScan? device and AI-assisted FibroScan? device [6]. - The R&D team grew to 112 members, a 6.67% increase, with the number of PhD holders rising from 8 to 36, providing a solid foundation for technological innovation [6]. Group 4: Global Market Expansion - The core product, the FibroScan? series diagnostic instruments, received multiple certifications including EU CE, US FDA, and China NMPA, and was included in liver disease detection guidelines by WHO and other authorities [7]. - In 2025, the company achieved overseas revenue of 1.064 billion, a 24.59% increase, accounting for 66.67% of total revenue; the subsidiary Echosens installed 1,691 units under a pay-per-use and leasing model, generating a net profit of 250 million, up 31.34% [7][8]. - The company deepened collaborations with global pharmaceutical companies like Boehringer Ingelheim, laying a foundation for sustained growth in overseas business [8].